NH Korindo Sekuritas Indonesia
Menu
  • Our Service
    • News & Research
      • News
      • Equity Report
      • Research Fixed Income
      • Company Report
      • Outlook
      • Special Notation
    • Equity
    • Fixed Income
    • Investment Banking
      • IPO
      • E-IPO
    • Download Center
      • Download NAIK
      • Documents
    • Wealth Management
      • Mutual Funds
    • Academy
      • Stock Dictionary
      • Stock Education
  • About Us
    • Our Firm
    • Our People
    • Our Branch
    • Corporate Governance
    • FAQ
  • Contact
  • Register Now
  • ID
  • EN

Kalbe Farma Tbk (KLBF) Stable Growth

  • Author
  • Recent Posts
NHKSI Research Team
NHKSI Research Team
NHKSI Research Team
Latest posts by NHKSI Research Team (see all)
  • Indeks Saham AS Kembali Menguat pada Perdagangan Kamis - March 31, 2023
  • Daily Report | 31 March 2023 - March 31, 2023
  • Information of PT Sarana Mitra Luas Tbk (SMIL) IPO - March 30, 2023

Single-Digit Growth in Sales
KLBF is projected to post the growth of 3.4% in 2018’s sales. The growth is a lot lower than the growth of 4.2% in 2017. It aligns the survey disclosing the decline in Indonesia’s retail sales growth from 3.5% in 2017 to 3.03% y-t-d in 2018.

Adjustment to Selling Prices of Pharmaceutical Drugs
The U.S. dollar strengthening further against the rupiah during 2018 leads to the adjustment to selling prices of pharmaceutical drugs by pharmaceutical companies; KLBF has raised the selling prices of its products by 3%-4% in 3Q18, for example.

Download full report HERE.

Share This Article

Related Article


Company Report | A Giant That Still Grows

27 Mar 2023

BBCA delivered an excellent performance throughout 2022. BBCA posted an FY22 Net Profit of IDR40.736 T, an increase of 29.6% YoY. This performance was also driven by an increase in NIM that rose by 20 bps YoY to 5.3% (FY22) from 5.1% (on a consolidated basis).

Company Report | High Raw Material Costs Caused Loss in 4Q22

24 Mar 2023

JPFA posted 4Q22 sales of IDR12.2 trillion (-1.1% QoQ; +0.9% YoY). Gross profit contracted by 26.1% YoY to IDR 1.5 trillion in 4Q22 due to higher production costs (+13.5% YoY), resulting in a lower GPM of 12.6%.

Company Report | Healthy Growth Strong Results —The Best Is Yet To Come

17 Mar 2023

BBNI has delivered a strong performance throughout 2022. BBNI posted their FY22 Net Profit of IDR 18.312 T, an increase of 68% YoY.

 

More Article

FI Business Trend

31 Mar 2023

Indeks Saham AS Kembali Menguat pada Perdaganga...

Indeks saham AS kembali menguat pada perdagangan Kamis (30/03/23) seiring mundurnya yie...

READ MORE

Daily Report

31 Mar 2023

Daily Report | 31 March 2023

The Dow Jones and others closed higher on Thursday (30/03/23), led by technology stocks...

READ MORE

IPO

30 Mar 2023

Information of PT Sarana Mitra Luas Tbk (SMIL) IPO

Perseroan berusaha di bidang rental forklift yang didirikan pada tahun 2006, dimana Per...

READ MORE

Contact Us

  • Treasury Tower 51th Floor, District 8, SCBD Lot 28, Jl. Jend. Sudirman No.Kav 52-53, RT.5/RW.3, Senayan, Kebayoran Baru, South Jakarta City, Jakarta 12190
  • cso@nhsec.co.id
  • +62 21 5088 9100 (Representative Number)
    +62 21 5088 9102 (CS Number)
  • +628 118 198 111 (Official Whatsapp 1)
    +6281 67 0000 5 (Official Whatsapp 2)

Link

  • Our Firm
  • Research
  • Our People
  • Download
  • Dictionary
  • FAQ
Find us
facebook twitter instagram youtube

PT NH Korindo Sekuritas Indonesia terdaftar dan diawasi oleh Otoritas Jasa Keuangan (OJK).


Copyright 2021 NH Korindo Sekuritas. All rights reserved.